Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AGNC Investment Corp (AGNC) vs Gilead Sciences, Inc. (GILD) Price & Performance

AGNC Investment CorpTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

AGNC Investment Corp vs Gilead Sciences, Inc. — how do they compare? AGNC Investment Corp trades at $10.91 (market cap $12.91B), while Gilead Sciences, Inc. trades at $136.54 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 13× AGNC Investment Corp's market cap, and AGNC Investment Corp pays the higher dividend (13.22%). Which is the better fit depends on your goals.

AGNCGILD
Market Cap
$12.91B$168.35B
Sector
FinancialsHealth
52-Week High
$12.17$155.80
52-Week Low
$9.46$110.56
Dividend Yield
13.22%2.42%
Enterprise Value
$191.42B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AGNC Investment Corp

AGNC Investment Corp. trades at $10.76, down 0.74% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The mortgage REIT reported strong profitability with a net income margin of 94.38% and ROE of 21.67% for 2025, while recent earnings beat expectations in Q1 and Q2 2026. Analysts maintain a consensus price target of $11.30, with 31% recommending Buy, though the majority (60%) suggest Hold.

AGNC offers a high dividend yield, supported by consistent payouts, but faces risks from interest rate sensitivity and leveraged mortgage securities. Upside potential exists if stable spreads persist, yet the stock's valuation above book value requires careful monitoring of portfolio performance and macroeconomic conditions.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.

The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AGNC Investment Corp

AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.

Read more on AGNC

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD